Papers
4
Total Citations
84
H-Index
3
About
Mauro Loi is a radiation oncologist whose research focuses on advancing stereotactic body radiotherapy (SBRT) and robotic radiosurgery for challenging cancer recurrences and oligometastatic disease. His major contributions center on demonstrating the feasibility and efficacy of robotic stereotactic retreatment for recurrent prostate cancer in previously irradiated patients, a high-risk scenario where conventional re-irradiation is often limited. His landmark 2017 study on this topic has garnered 50 citations, establishing a foundation for safe salvage therapy. Loi also leads innovative trials in breast cancer, notably the phase II ROCK trial (NCT03520894), which investigates preoperative robotic radiosurgery for early breast cancer—a paradigm-shifting approach that treats a well-defined target before surgery, potentially reducing toxicity. This work, published in 2022 with 29 citations, highlights his role in translating advanced technology into clinical practice. Additionally, he has explored robotic SBRT for pancreatic metastases, contributing to the growing evidence for non-invasive treatment of visceral oligometastases. Through these efforts, Loi has shaped modern radiation oncology by expanding the therapeutic window for re-irradiation and refining dose delivery in sensitive anatomical sites.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4